Protagenic Therapeutics Inc. (PTIX): יחס שווי שוק להכנסות

Effective management at Protagenic Therapeutics (PTIX) ensures strict control over R&D expenses, which is confirmed by the current P/S level on the chart; captures the magnitude of this parameter. Robotic protein analysis accelerates the search for neurodegeneration treatments by minimizing manual labor. The strategy is further complemented by independent preclinical development of neuropeptides and research alliances with scientific institutes.

To filter blue-chip assets, investors must distinguish market expectations from actual operational efficiency. This indicator correlates market capitalization with annual turnover to determine the cost per unit of revenue, which, for Protagenic Therapeutics (PTIX), a company focused on preclinical neuropeptide research without external support, makes the price-to-sales chart a key tool for assessing the speculative premium attached to future discoveries.